We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2.18%. Estimates have gone up slightly over the past 7 days.
Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on third quarter earnings - the company reported EPS of $1.90 while our consensus called for EPS of $1.80.
Revenues Beat: Revenues were also above expectations. Johnson & Johnson posted revenues of $19.65 billion, compared to our consensus estimate of $19.28 billion.
Higher sales from new products as well as the positive contribution from recent acquisitions like Actelion pulled up the top line in the quarter.
Key Statistics: Pharmaceutical segment sales rose 15.4% year over year to $9.7 billion, reflecting 14.6% operational growth and 0.8% positive currency impact as sales rose in both the domestic and international markets.
Ups 2017 View: J&J raised its adjusted earnings and sales outlook for the year.
J&J expects 2017 adjusted earnings per share in the range of $7.25 - $7.30 compared with $7.12 - $7.22 expected previously.
The revenue guidance was raised to a range of $76.1 billion to $76.5 billion compared with $75.8 billion to $76.1 billion expected previously.
Stock Price Impact: Shares rose 1.6% in pre-market trading.
Check back later for our full write up on this JNJ earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2017 View
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2.18%. Estimates have gone up slightly over the past 7 days.
Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on third quarter earnings - the company reported EPS of $1.90 while our consensus called for EPS of $1.80.
Revenues Beat: Revenues were also above expectations. Johnson & Johnson posted revenues of $19.65 billion, compared to our consensus estimate of $19.28 billion.
Higher sales from new products as well as the positive contribution from recent acquisitions like Actelion pulled up the top line in the quarter.
Key Statistics: Pharmaceutical segment sales rose 15.4% year over year to $9.7 billion, reflecting 14.6% operational growth and 0.8% positive currency impact as sales rose in both the domestic and international markets.
Ups 2017 View: J&J raised its adjusted earnings and sales outlook for the year.
J&J expects 2017 adjusted earnings per share in the range of $7.25 - $7.30 compared with $7.12 - $7.22 expected previously.
The revenue guidance was raised to a range of $76.1 billion to $76.5 billion compared with $75.8 billion to $76.1 billion expected previously.
Stock Price Impact: Shares rose 1.6% in pre-market trading.
Johnson & Johnson Price and Consensus
Johnson & Johnson Price and Consensus | Johnson & Johnson Quote
Check back later for our full write up on this JNJ earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>